This report complements Expenditure on health
for Aboriginal and Torres Strait Islander people 2010-11 (AIHW 2013a) by
providing a more detailed analysis of health expenditure estimates for
Indigenous and non-Indigenous Australians in 2010-11. Estimates are
disaggregated at the regional level, as well as for specific disease and injury
Health expenditure by remoteness
analysed for selected health services (i.e. admitted patients, Aboriginal
Community Controlled Health Services, Medicare Benefits Schedule and
Pharmaceutical Benefits Scheme). For these services, for every dollar spent
per non-Indigenous Australian, $1.52 was spent per Indigenous Australian and
expenditure increased with remoteness for both Indigenous and non-Indigenous
The difference was greatest in Remote/Very remote
areas where, for every dollar spent per non-Indigenous Australian, $2.22 was
spent per Indigenous Australian. The higher expenditure on Aboriginal and
Torres Strait Islander people in remote areas is mainly due to higher
expenditure on admitted patient services.
Health expenditure by disease
The disease groups that accounted for the highest proportion of
admitted patient expenditure for Aboriginal and Torres Strait Islander people
were genitourinary diseases ($195 million, or 11% of Indigenous admitted
patient expenditure), which includes the cost of dialysis treatment, followed
by mental and behavioural disorders ($191 million or 11%), unintentional
injuries ($149 million or 8%) and maternal conditions ($144 million or
The largest disease group of admitted patient expenditure for
non-Indigenous Australians was cardiovascular disease ($5,171 million, or 12%
of non-Indigenous admitted patient expenditure).
Overall, for every dollar spent on potentially
preventable hospitalisations (PPH) per non-Indigenous Australian, $2.22 was
spent per Indigenous Australian.
The highest expenditure on PPH for
Indigenous Australians was for chronic obstructive pulmonary disease ($36
million, or 16% of Indigenous PPH expenditure), followed by diabetes
complications ($35 million or 16%) and cellulitis ($20 million or 9%).
Expenditure on vaccine-preventable conditions was $21 per Indigenous
Australian and $5 per non- Indigenous Australian.